Real-world outcomes of Citrobacter freundii , Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies
Journal of Antimicrobial Chemotherapy · 03.11.2026 · 81 (12)
DOI: 10.1093/jac/dkag377 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.11.2026. Verfasst von Jasanjeet Jawanda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Good Samaritan Hospital, Vincennes, IN, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Cefepime, Enterobacter cloacae. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
To determine comparative effectiveness of piperacillin/tazobactam and cefepime for the treatment of bacteremia due to Enterobacterales at moderate risk for clinically significant AmpC production.
Methods
A retrospective multicentre study was conducted among adults with bacteremia due to Enterobacter cloacae complex, Klebsiella aerogenes, or Citrobacter freundii complex from 2017 to 2025. Treatment-emergent resistance was defined as a ≥4-fold MIC increase or a categorical change in susceptibility within 90 days.
Results
Seven hundred twenty-eight patients met inclusion criteria. The median (IQR) age was 67 years (55–74), and 35% (252/728) were immunocompromised. Cefepime was used for definitive therapy in 47% (342/728), followed by piperacillin/tazobactam in 18% (129/728) and carbapenems in 16% (115/728). Overall, 30-day mortality was 12% (88/728). Patients receiving piperacillin/tazobactam had a higher median (IQR) Pitt bacteremia score (2 [1–3] versus 1 [0–3], P=0.017) than those receiving cefepime, but rates of 30-day mortality (14% [18/129] versus 11% [37/342], P = 0.345) and relapsed infection between days 5–14 (3% [4/129] versus 2% [5/342], P = 0.266) were similar. After inverse probability of treatment weighting, 30-day mortality rates between patients treated with piperacillin/tazobactam and cefepime were not significantly different (HR 1.05, 95% CI 0.57–1.92). Treatment-emergent resistance to definitive therapy occurred in 1% (5/342), 2% (3/129), and 3% (4/115) of patients treated with cefepime, piperacillin/tazobactam, and carbapenems, respectively.
Conclusions
In the largest study to date of bacteremia due to E. cloacae complex, K. aerogenes, or C. freundii complex, treatment-emergent resistance was uncommon, and outcomes did not differ significantly between patients treated with piperacillin/tazobactam and cefepime.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Good Samaritan Hospital, Vincennes, IN, USA.
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
- Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
ORCID-Profile: Jasanjeet Jawanda, Ryan K Shields, Hannah Creager
Zitieren
APA
Jawanda, J., Shields, R. K., Balasubramani, G. K., Clarke, L., Creager, H., Falcione, B. A., Marini, R., O'Donnell, M., Peng, L., & Shah, S. (2026). Real-world outcomes of Citrobacter freundii , Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies. Journal of Antimicrobial Chemotherapy, 81(12). https://doi.org/10.1093/jac/dkag377
Vancouver
Jawanda J, Shields RK, Balasubramani GK, Clarke L, Creager H, Falcione BA, et al. Real-world outcomes of Citrobacter freundii , Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies. Journal of Antimicrobial Chemotherapy. 2026;81(12). doi:10.1093/jac/dkag377
BibTeX
@article{Jawanda2026,
author = {Jawanda, Jasanjeet and Shields, Ryan K and Balasubramani, G K and Clarke, Lloyd and Creager, Hannah and Falcione, Bonnie A and Marini, Rachel and O'Donnell, Matthew and Peng, Lingyi and Shah, Sunish},
title = {Real-world outcomes of Citrobacter freundii , Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {12},
doi = {10.1093/jac/dkag377}
}
EUVIMED